NEJM Clinician: Apixaban Vs. Rivaroxaban for Acute VTE

Why It Matters

The trial demonstrates a clear safety advantage for apixaban, guiding clinicians toward a lower‑bleeding anticoagulant choice for acute VTE management.

Key Takeaways

• Head-to-head trial compares apixaban vs rivaroxaban in acute VTE
• Clinically important bleeding twice as likely with rivaroxaban
• Number needed to harm is 26 favoring apixaban
• Clot recurrence rates similar between both anticoagulants in study
• Dosing convenience and insurance may influence drug selection

Summary

The New England Journal of Medicine published a head‑to‑head trial evaluating apixaban (Eliquis) against rivaroxaban (Xarelto) in 2,800 patients with acute pulmonary embolism or deep‑vein thrombosis. The study provides the first direct comparative safety and efficacy data for these two widely used direct oral anticoagulants.

Over a three‑month follow‑up, clinically important bleeding occurred twice as often in the rivaroxaban arm, translating to a number needed to harm of 26. In contrast, recurrence of thrombotic events was low and virtually identical between the two groups, indicating comparable efficacy.

The presenting clinician emphasized, “a pixiban should be the preferred choice for most patients,” while acknowledging that some may favor rivaroxaban for its once‑daily dosing or due to insurance coverage constraints. The commentary underscores real‑world factors that often influence prescribing beyond pure clinical outcomes.

For providers, the findings suggest prioritizing apixaban when safety is paramount, especially in patients at higher bleeding risk. Payers and formulary committees may also reconsider drug placement, balancing the modest convenience advantage of rivaroxaban against its higher bleeding liability.

Original Description

Is apixaban safer than rivaroxaban for acute venous thromboembolism (VTE)?

NEJM Clinician Editor-in-Chief, Raja-Elie Abdulnour, MD, describes the first head-to-head trial comparing the bleeding risks of these two direct-acting oral anticoagulants. Visit clinician.nejm.org for the full context and comment.